| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440675 | European Journal of Cancer | 2017 | 9 Pages |
Abstract
Improvement in OS with pembrolizumab was not statistically significant at either dose versus chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Omid Hamid, Igor Puzanov, Reinhard Dummer, Jacob Schachter, Adil Daud, Dirk Schadendorf, Christian Blank, Lee D. Cranmer, Caroline Robert, Anna C. Pavlick, Rene Gonzalez, F. Stephen Hodi, Paolo A. Ascierto, April K.S. Salama, Kim A. Margolin,